C16orf3 Inhibitors

Wortmannin and LY294002 are inhibitors of PI3K, an upstream regulator of many cellular functions, including growth, survival, and metabolism, which can be influenced by C16orf3. Rapamycin, by inhibiting mTOR, can disrupt central processes like protein synthesis and cell growth, potentially intersecting with the functional domain of C16orf3. SB203580, PD98059, and U0126 are specific kinase inhibitors that target p38 MAP kinase and MEK1/2, respectively, altering the stress response and MAPK/ERK signaling pathways, which are crucial for cell differentiation and proliferation that C16orf3 might control. SP600125 and Dasatinib offer inhibition of JNK and Src family kinases, respectively, which can affect apoptosis and cell migration, processes where C16orf3 could play a regulatory role.

PP2 further extends the reach of kinase inhibition to Src family kinases, potentially impacting cell adhesion and growth. NF449 disrupts G protein-coupled receptor signaling, which is pivotal in transducing extracellular signals into cellular responses, a cascade that C16orf3 could be part of. Triptolide acts by inhibiting transcription factors, thereby potentially influencing gene expression patterns and cellular signaling networks involving C16orf3. Axitinib, targeting VEGFR tyrosine kinases, can modulate angiogenesis and proliferation, further expanding the impact on biological processes in which C16orf3 may be involved.